Lacosamide

Lacosamide, the active ingredient in Lacosamide, is an Anticonvulsant presented as a tablet for oral use. It treats partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anticonvulsant indicated for seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. Adjunctive therapy for epilepsy: used alongside other antiepileptic drugs to improve overall seizure control. Focal seizures: helps control seizures that originate in a specific brain region.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of queasiness or urge to vomit. - Headache: mild to moderate cranial pain. - Fatigue: unusual tiredness or lack of energy. - Visual disturbances: blurred or double vision. - Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects: - Cardiac arrhythmias: including PR‑interval prolongation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive or suicidal ideation. - Liver injury: abnormal liver function tests or hepatitis.

When prescribing Lacosamide, clinicians should consider several safety and handling precautions.

Renal impairment: adjust dose in patients with reduced kidney function. Hepatic impairment: monitor liver function and consider dose modification. Cardiac conduction: avoid in patients with known PR‑interval prolongation or other conduction disorders. Concomitant CNS depressants: may increase sedation when combined. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at ambient temperature: keep below 25°C in original container, protect from moisture.

Lacosamide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: strong enzyme inducer reduces lacosamide plasma levels. - Phenytoin: may lower lacosamide concentrations. - Phenobarbital: decreases lacosamide exposure. - Rifampin: induces metabolism, lowering efficacy.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may increase sedation. - Alcohol: can enhance central nervous system effects. - Other antiepileptics (e.g., valproate): monitor for additive toxicity. - QT‑prolonging drugs: monitor cardiac rhythm for potential prolongation.